000 | 05022nam a22004093i 4500 | ||
---|---|---|---|
001 | EBC6422751 | ||
003 | MiAaPQ | ||
005 | 20220324112733.0 | ||
006 | m o d | | ||
007 | cr cnu|||||||| | ||
008 | 220324s2018 xx o ||||0 eng d | ||
020 |
_a9783662564653 _q(electronic bk.) |
||
020 | _z9783662564646 | ||
035 | _a(MiAaPQ)EBC6422751 | ||
035 | _a(Au-PeEL)EBL6422751 | ||
035 | _a(OCoLC)1034550627 | ||
040 |
_aMiAaPQ _beng _erda _epn _cMiAaPQ _dMiAaPQ |
||
050 | 4 | _aR895-920 | |
100 | 1 | _aSpeck, Ulrich. | |
245 | 1 | 0 |
_aX-Ray Contrast Media : _bOverview, Use and Pharmaceutical Aspects. |
250 | _a5th ed. | ||
264 | 1 |
_aBerlin, Heidelberg : _bSpringer Berlin / Heidelberg, _c2018. |
|
264 | 4 | _c�2018. | |
300 | _a1 online resource (128 pages) | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
505 | 0 | _aIntro -- CONTENT -- 1 INTRODUCTION -- Historical Aspects -- Contrast media in X-ray imaging -- Visualization of functions -- Morphology -- 2 GENERAL PRINCIPLES OF X-RAY CONTRAST MEDIA -- Physical Principles -- 3 STRUCTURE AND PROPERTIES OF X-RAY CONTRAST MEDIA -- Barium Sulfate -- Lipiodol -- Water-soluble contrast media -- Chemical structure, biological behavior and use -- High-osmolar, ionic contrast media -- Low-osmolar substances -- Nonionic contrast media -- Osmolality and side effects caused by hypertonicity -- Ionic contrast media -- Contrast media for intravenous cholegraphy -- Cations -- Synthesis of water-soluble contrast media -- 4 DEGRADATION OF IODINATED X-RAY CONTRAST MEDIA -- 5 PHYSICOCHEMICAL PROPERTIES OF WATER-SOLUBLE CONTRAST MEDIA -- Water solubility -- Viscosity/Temperature -- Osmolality -- Hydrophilia/Lipophilia -- Electrical charge -- Specific gravity/Density -- Others -- 6 PHARMACEUTICAL PRODUCT QUALITY -- Practical information at a glance -- Purity of the active ingredient, by-products and degradation products -- Formulations -- Additives -- Microbiological quality of the finished product -- Production under controlled environmental conditions -- Production process -- Sterile filtration, ultrafiltration and sterilization -- Sterility test -- Test for pyrogens -- Preservation of product quality in hospitals and practices -- Stability in long-term storage and at different temperatures -- Sensitivity to irradiation and light: white glass, brown glass, and UV-protective foil -- Tests for contamination with particles -- Risks of microbial contamination -- Transferring the contrast medium to sterile containers, disposable syringes, automatic injectors -- Transferring to sterile containers -- Drawing-up into disposable syringes or automatic injectors -- Use of large-volume CM bottles -- 7 PHARMACOLOGICAL PROPERTIES OF CM. | |
505 | 8 | _aBiochemical-pharmacological properties -- Protein binding -- Complement activation -- Enzyme inhibition -- Influence on blood cells -- Histamine release -- Pharmacological-Toxicological Properties -- Tolerance limits -- Effects on the cardiovascular system -- Influence on renal function -- Allergic and pseudoallergic hypersensitivity reactions -- Endothelial damage -- Nervous system -- Pharmacokinetics -- 8 USES OF X-RAY CONTRAST MEDIA -- Modes of opacification -- 9 INTERACTIONS -- Influence on laboratory tests -- Interaction with medications -- Interaction of contrast media with additives and during interventional procedures -- Effects on blood coagulation -- 10 RISKS OF CONTRAST MEDIA USE -- Barium sulfate -- Ionic contrast media -- Nonionic contrast media -- Delayed reactions -- Causes of contrast media reactions -- General reactions (anaphylactoid reactions) -- Prophylaxis of general reactions -- Dose-dependent side effects -- Prophylaxis and therapy of severe iodine-induced hyperthyroidism -- Renal damage -- Renal insufficiency -- Plasmocytoma -- Diabetes mellitus -- Prophylaxis -- Pregnant patients -- Breast-feeding mothers -- Pheochromocytoma -- Sickle-cell anemia -- 11 DRUGS AND MEASURES FOR THE TREATMENT OF A CONTRAST MEDIUM REACTION -- Notes on the prophylaxis and therapy of X-ray contrast medium adverse effects -- Main risk factors* and prophylactic measures on use of X-ray contrast media -- First line treatment of contrast medium adverse reactions -- 12 FURTHER DEVELOPMENT OF CONTRAST MEDIA -- REFERENCES. | |
588 | _aDescription based on publisher supplied metadata and other sources. | ||
590 | _aElectronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2022. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. | ||
655 | 4 | _aElectronic books. | |
776 | 0 | 8 |
_iPrint version: _aSpeck, Ulrich _tX-Ray Contrast Media _dBerlin, Heidelberg : Springer Berlin / Heidelberg,c2018 _z9783662564646 |
797 | 2 | _aProQuest (Firm) | |
856 | 4 | 0 |
_uhttps://www.nbs.de/bibliothek/faq _zWie greife ich auf das E-Book zu? |
856 | 4 | 0 |
_uhttps://ebookcentral.proquest.com/lib/nbsde/detail.action?docID=6422751 _zClick to View |
999 |
_c2334 _d2334 |